NCT00284271 is a Phase 2 clinical trial of Cyclophosphamide in Hodgkin´s Lymphoma, sponsored by University of Cologne.

Who is sponsoring NCT00284271?

NCT00284271 is sponsored by University of Cologne.

What drugs are being tested in NCT00284271?

Interventions in NCT00284271: Cyclophosphamide, Adramycin, Procarbacine, Prednisone, Vincristine, Bleomycin, Erythropoietin beta.

What condition does NCT00284271 study?

NCT00284271 studies Hodgkin´s Lymphoma.

Is NCT00284271 still recruiting?

NCT00284271 is currently completed. Last updated 28 July 2011.

Last reviewed 2011-07-28 · How we verify

NCT00284271

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

Completed Phase 2 Last updated 28 July 2011

What this trial tests

Phase 2 trial testing Cyclophosphamide in Hodgkin´s Lymphoma in 65 participants. Completed.

Timeline

1 January 2004

Primary endpoint
1 December 2005

Quick facts

Lead sponsor	University of Cologne
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	65
Start date	1 January 2004
Primary completion	1 December 2005
Sites	1 location across Germany

Drugs / interventions tested

Cyclophosphamide (cyclophosphamide) — full drug profile →
Adramycin — full drug profile →
Procarbacine
Prednisone (prednisone) — full drug profile →
Vincristine (vincristine) — full drug profile →
Bleomycin (BLEOMYCIN) — full drug profile →
Erythropoietin beta

Conditions studied

Hodgkin´s Lymphoma — all drugs for Hodgkin´s Lymphoma →

Sponsor

University of Cologne

Who can join

Adults 61 to 75, any sex, with Hodgkin´s Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Halbsguth TV, Nogová L, Mueller H, Sieniawski M, et al · · 2010 · cited 33× · PMID 20551376 · DOI 10.1182/blood-2009-11-253211

Verify or expand the search:

Other trials of Cyclophosphamide

Trials testing the same drug.

NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07509008 — Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Manageme · Phase 1, PHASE2 · not yet recruiting
NCT07444632 — Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/ · Phase 1 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT07437963 — Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatmen · Phase 1, PHASE2 · not yet recruiting

Other University of Cologne trials

Trials by the same sponsor.

NCT07280585 — STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease · Phase 3 · recruiting
NCT06612515 — Vaccine-induced Immunity in Immunocompromised Patients · recruiting
NCT06781710 — Analysis of the Epidemiology, Clinical Presentation and Therapy as Well as Therapy-associated Risk of Demyelination Synd · recruiting
NCT05969431 — Hair Cortisol as Marker of Chronic Stress in Preterm and Term Fathers - Fathair-study · recruiting
NCT05876221 — Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00284271 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Cologne
Last refreshed: 28 July 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00284271.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing